JP2009508834A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009508834A5 JP2009508834A5 JP2008530623A JP2008530623A JP2009508834A5 JP 2009508834 A5 JP2009508834 A5 JP 2009508834A5 JP 2008530623 A JP2008530623 A JP 2008530623A JP 2008530623 A JP2008530623 A JP 2008530623A JP 2009508834 A5 JP2009508834 A5 JP 2009508834A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- amount
- antifoam
- calcium
- range
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000009472 formulation Methods 0.000 claims 20
- 239000000203 mixture Substances 0.000 claims 20
- 239000002518 antifoaming agent Substances 0.000 claims 17
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims 7
- 229940122361 Bisphosphonate Drugs 0.000 claims 7
- 150000004663 bisphosphonates Chemical class 0.000 claims 7
- 230000015572 biosynthetic process Effects 0.000 claims 6
- 239000006260 foam Substances 0.000 claims 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 5
- 229940062527 alendronate Drugs 0.000 claims 5
- 208000001132 Osteoporosis Diseases 0.000 claims 4
- 229940069978 calcium supplement Drugs 0.000 claims 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims 4
- 210000002784 stomach Anatomy 0.000 claims 4
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 4
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 3
- 229940008099 dimethicone Drugs 0.000 claims 3
- 239000004205 dimethyl polysiloxane Substances 0.000 claims 3
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical group O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 229960002061 ergocalciferol Drugs 0.000 claims 3
- 229940083037 simethicone Drugs 0.000 claims 3
- 235000001892 vitamin D2 Nutrition 0.000 claims 3
- 239000011653 vitamin D2 Substances 0.000 claims 3
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims 3
- 235000005282 vitamin D3 Nutrition 0.000 claims 3
- 239000011647 vitamin D3 Substances 0.000 claims 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims 3
- 229940021056 vitamin d3 Drugs 0.000 claims 3
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims 2
- 229960004343 alendronic acid Drugs 0.000 claims 2
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 claims 2
- 229960002535 alfacalcidol Drugs 0.000 claims 2
- 229940069428 antacid Drugs 0.000 claims 2
- 239000003159 antacid agent Substances 0.000 claims 2
- 230000001458 anti-acid effect Effects 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- -1 polydimethylsiloxanes Polymers 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 229940057779 calci-chew Drugs 0.000 claims 1
- 229960005084 calcitriol Drugs 0.000 claims 1
- 235000020964 calcitriol Nutrition 0.000 claims 1
- 239000011612 calcitriol Substances 0.000 claims 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims 1
- 239000001110 calcium chloride Substances 0.000 claims 1
- 229910001628 calcium chloride Inorganic materials 0.000 claims 1
- 229960002713 calcium chloride Drugs 0.000 claims 1
- 235000011148 calcium chloride Nutrition 0.000 claims 1
- 239000004227 calcium gluconate Substances 0.000 claims 1
- 229960004494 calcium gluconate Drugs 0.000 claims 1
- 235000013927 calcium gluconate Nutrition 0.000 claims 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims 1
- 229960002401 calcium lactate Drugs 0.000 claims 1
- 239000001527 calcium lactate Substances 0.000 claims 1
- 235000011086 calcium lactate Nutrition 0.000 claims 1
- 159000000007 calcium salts Chemical group 0.000 claims 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims 1
- HJKBJIYDJLVSAO-UHFFFAOYSA-L clodronic acid disodium salt Chemical compound [Na+].[Na+].OP([O-])(=O)C(Cl)(Cl)P(O)([O-])=O HJKBJIYDJLVSAO-UHFFFAOYSA-L 0.000 claims 1
- 229940009626 etidronate Drugs 0.000 claims 1
- 229940083571 etidronate disodium Drugs 0.000 claims 1
- GWBBVOVXJZATQQ-UHFFFAOYSA-L etidronate disodium Chemical compound [Na+].[Na+].OP(=O)([O-])C(O)(C)P(O)([O-])=O GWBBVOVXJZATQQ-UHFFFAOYSA-L 0.000 claims 1
- 229940015872 ibandronate Drugs 0.000 claims 1
- 150000005324 oxide salts Chemical class 0.000 claims 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims 1
- 229960003978 pamidronic acid Drugs 0.000 claims 1
- 229940089617 risedronate Drugs 0.000 claims 1
- 229960000759 risedronic acid Drugs 0.000 claims 1
- 229940079488 strontium ranelate Drugs 0.000 claims 1
- XXUZFRDUEGQHOV-UHFFFAOYSA-J strontium ranelate Chemical compound [Sr+2].[Sr+2].[O-]C(=O)CN(CC([O-])=O)C=1SC(C([O-])=O)=C(CC([O-])=O)C=1C#N XXUZFRDUEGQHOV-UHFFFAOYSA-J 0.000 claims 1
- 229960005324 tiludronic acid Drugs 0.000 claims 1
- 229960004276 zoledronic acid Drugs 0.000 claims 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0518952A GB2430156A (en) | 2005-09-16 | 2005-09-16 | Bisphosphonate formulation |
| GB0610311A GB0610311D0 (en) | 2006-05-24 | 2006-05-24 | Bisphosphonate formulation |
| PCT/GB2006/003457 WO2007031785A2 (en) | 2005-09-16 | 2006-09-15 | Bisphosphonate formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009508834A JP2009508834A (ja) | 2009-03-05 |
| JP2009508834A5 true JP2009508834A5 (https=) | 2009-06-18 |
Family
ID=37865306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008530623A Pending JP2009508834A (ja) | 2005-09-16 | 2006-09-15 | ビスホスホネート製剤 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1937362B1 (https=) |
| JP (1) | JP2009508834A (https=) |
| AU (1) | AU2006290519B2 (https=) |
| BR (1) | BRPI0615770A2 (https=) |
| CA (1) | CA2622322A1 (https=) |
| NZ (1) | NZ567200A (https=) |
| WO (1) | WO2007031785A2 (https=) |
| ZA (1) | ZA200803086B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1972341A1 (en) * | 2007-03-23 | 2008-09-24 | Novartis AG | Pharmaceutical compositions comprising a bisphosphonate and vitamin D |
| EP2055297A1 (en) * | 2007-11-05 | 2009-05-06 | Merz Pharma GmbH & Co. KGaA | Therapy option for recoloration of hair via bisphosphonates by physiological repigmentation with age-related and/or premature "grayed" patients |
| TR200900879A2 (tr) * | 2009-02-05 | 2010-08-23 | Bi̇lgi̇ç Mahmut | Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler |
| TR200900878A2 (tr) * | 2009-02-05 | 2010-08-23 | Bi̇lgi̇ç Mahmut | Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL129127A0 (en) * | 1996-10-04 | 2000-02-17 | Merck & Co Inc | Liquid alendronate formulations |
| US5914135A (en) | 1997-04-16 | 1999-06-22 | Mcneil-Ppc, Inc. | Liquid antacid compositions |
| US6015801A (en) * | 1997-07-22 | 2000-01-18 | Merck & Co., Inc. | Method for inhibiting bone resorption |
| PT1175904E (pt) * | 1997-07-22 | 2007-04-30 | Merck & Co Inc | Alendronato para utilização no tratamento da osteoporose |
| US20040062802A1 (en) * | 1998-04-02 | 2004-04-01 | Hermelin Victor M. | Maximizing effectiveness of substances used to improve health and well being |
| AU2001251432A1 (en) * | 2000-04-07 | 2001-10-23 | The Board Of Regents Of The University Of Texas System | Unique compositions of zwitterionic phospholipids and bisphosphonates and use ofthe compositions as bisphosphate delivery systems with reduced gi toxicity |
| GB0029111D0 (en) * | 2000-11-29 | 2001-01-10 | Novartis Ag | Organic compounds |
| JP2005516928A (ja) * | 2001-12-13 | 2005-06-09 | メルク エンド カムパニー インコーポレーテッド | 骨異常のためのビスホスホネート液体製剤 |
| CA2488581C (en) * | 2002-03-28 | 2011-06-07 | The Procter & Gamble Company | Hair bleach kit comprising a colorant for improved visual application |
| US7595345B2 (en) * | 2003-11-20 | 2009-09-29 | Eli Lilly And Company | Vitamin D receptor modulators |
| DK2283825T3 (da) | 2004-05-24 | 2022-06-27 | Theramex Hq Uk Ltd | Enterisk fast oral doseringsform af en bisfosfonat indeholdende et chelateringsmiddel |
-
2006
- 2006-09-15 WO PCT/GB2006/003457 patent/WO2007031785A2/en not_active Ceased
- 2006-09-15 BR BRPI0615770-0A patent/BRPI0615770A2/pt not_active IP Right Cessation
- 2006-09-15 NZ NZ567200A patent/NZ567200A/en not_active IP Right Cessation
- 2006-09-15 CA CA002622322A patent/CA2622322A1/en not_active Abandoned
- 2006-09-15 EP EP06779468A patent/EP1937362B1/en not_active Not-in-force
- 2006-09-15 AU AU2006290519A patent/AU2006290519B2/en not_active Ceased
- 2006-09-15 JP JP2008530623A patent/JP2009508834A/ja active Pending
-
2008
- 2008-04-08 ZA ZA2008/03086A patent/ZA200803086B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6067466B2 (ja) | 骨粗鬆症の治療および予防用のビスホスホン酸 | |
| US5853759A (en) | Effervescent alendronate formulation | |
| ES2524690T3 (es) | Composición farmacéutica de liberación sostenida a largo plazo que contiene una suspensión acuosa de bisfosfonato | |
| US20090053162A1 (en) | Bisphosphonate Formulation | |
| JP2009167200A (ja) | 発泡性ビスホスホネート製剤 | |
| US20100144679A1 (en) | Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture | |
| JP2004528303A5 (https=) | ||
| Slatopolsky et al. | Proceedings: Pathogenesis and Treatment of Renal Osteodystrophy | |
| MX2012002786A (es) | Composiciones farmaceuticas que comprenden derivados biofosfonato y colecalciferol en alta dosis. | |
| WO2008116809A1 (en) | Pharmaceutical compositions comprising a bisphosphonate and vitamin d | |
| JP2009508834A5 (https=) | ||
| Chaiamnuay et al. | Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates? | |
| JP2010513328A5 (https=) | ||
| JP2009508834A (ja) | ビスホスホネート製剤 | |
| US20060034921A1 (en) | Effervescent bisphosphonate formulation | |
| JP2010513475A (ja) | リセドロネートおよびビタミンｄ組成物 | |
| GB2430156A (en) | Bisphosphonate formulation | |
| US20070087052A1 (en) | Effervescent bisphosphonate formulation | |
| Bartl et al. | Bisphosphonates: The Success Story in Osteoporosis | |
| ME00862B (me) | Upotreba bisfosfonata za proizvodnju leka za inhibiranje resorpcije kostiju | |
| WO2006133097A2 (en) | Use of alternating amine and non-amine bisphosphonate combinations for treating osteoporosis |